Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

Design and eligibility criteria of primary prevention trials

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

Serious vascular events in primary prevention trials-proportional effects of aspirin allocation

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

Serious vascularevents in primary

preventionTrials-subgroup

analyses

ATT Collaboration. Lancet 2009;373:1849-60

Comparison of proportional and absolute effects of aspirin in primary and secondary prevention trials

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

Selected outcomes in primary

and secondary prevention

trials of aspirin, by sex

ATT Collaboration. Lancet 2009;373:1849-60

Stroke subtypes in primary and

secondary prevention trials

ATT Collaboration. Lancet 2009;373:1849-60

Mortality by cause in primary prevention trials

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

Rate ratios (95% CI) associated with risk factors for selected outcomes in people with no known

vascular disease in primary prevention trials

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

Predicted 5-year absolute eff ects of

allocation to aspirin in different categories of

age and sex in theprimary and

secondary prevention trials (ignoring non-vascular mortality)

ATT Collaboration. Lancet 2009;373:1849-60

Predicted 5-year absolute effects of allocation to aspirin in the primary

prevention trials in different categories of

5-year risk (if untreated)of coronary heart disease

(CHD) (ignoring non-vascular mortality)

ATT Collaboration. Lancet 2009;373:1849-60